Arusha International Conference Centre (meeting only) Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2009
Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Tuberculosis: Science Aimed at Ending the Epidemic (S9)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Overcoming the Crisis of TB and AIDS (T2)
Organizer(s) Anne E. Goldfeld and Stefan H.E. Kaufmann
October 20—25, 2009
Arusha International Conference Centre (meeting only) • Arusha, Tanzania
Abstract Deadline: Jun 22, 2009
Late Abstract Deadline: Jul 22, 2009
Scholarship Deadline: Jun 22, 2009
Early Registration Deadline: Aug 20, 2009
Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
Tuberculosis (TB) is the largest cause of death in the AIDS setting, having caused approximately 50% of all AIDS deaths globally. Each infection on its own manipulates the host immune response to enhance the other infection’s pathogenicity, and the treatment of each involves long or lifelong therapy of complicated drug regimens. The focus of this Keystone Symposia meeting is to gain deeper insights into the immune pathology and deadly synergism between HIV and TB and its global toll in order to identify new ways to solve this global catastrophe by way of basic scientific discovery, and the development and delivery of vaccines, drugs and care. Mycobacterium tuberculosis survives in the vast majority of infected individuals without causing disease. However, as HIV compromises the immune system it fuels clinical emergence of TB and, as a result, has become the driving force for the current TB epidemics in Subsaharan Africa and Asia. TB in turn drives HIV-1 replication and causes HIV-1 disease progression. In order to effectively tackle this twin epidemic, integrated approaches encompassing basic immunological research, drug discovery, drug and vaccine design and delivery and novel approaches to delivering care in remote and impoverished areas must be integrated. This includes the following: virologic and bacteriologic research on the pathogens themselves; immunologic, molecular and cellular research on the host response; design, development and delivery of drugs and vaccines; development of different technologies for biomarkers of disease and cure; and novel drug and vaccine delivery systems. Moreover, basic discovery must be synergized with novel approaches to the delivery of TB and AIDS care in endemic areas. The overarching goal of the symposium is to gain a broad perspective on the problem of TB/AIDS – from its impact on life on earth to the basic biology of the organisms, the immune response – and to develop new paradigms of thinking and responses to deal with the humanitarian catastrophe of TB and AIDS co-infection.
View Scholarships/Awards
Tuberculosis (TB) is the largest cause of death in the AIDS setting, having caused approximately 50% of all AIDS deaths globally. Each infection on its own manipulates the host immune response to enhance the other infection’s pathogenicity, and the treatment of each involves long or lifelong therapy of complicated drug regimens. The focus of this Keystone Symposia meeting is to gain deeper insights into the immune pathology and deadly synergism between HIV and TB and its global toll in order to identify new ways to solve this global catastrophe by way of basic scientific discovery, and the development and delivery of vaccines, drugs and care. Mycobacterium tuberculosis survives in the vast majority of infected individuals without causing disease. However, as HIV compromises the immune system it fuels clinical emergence of TB and, as a result, has become the driving force for the current TB epidemics in Subsaharan Africa and Asia. TB in turn drives HIV-1 replication and causes HIV-1 disease progression. In order to effectively tackle this twin epidemic, integrated approaches encompassing basic immunological research, drug discovery, drug and vaccine design and delivery and novel approaches to delivering care in remote and impoverished areas must be integrated. This includes the following: virologic and bacteriologic research on the pathogens themselves; immunologic, molecular and cellular research on the host response; design, development and delivery of drugs and vaccines; development of different technologies for biomarkers of disease and cure; and novel drug and vaccine delivery systems. Moreover, basic discovery must be synergized with novel approaches to the delivery of TB and AIDS care in endemic areas. The overarching goal of the symposium is to gain a broad perspective on the problem of TB/AIDS – from its impact on life on earth to the basic biology of the organisms, the immune response – and to develop new paradigms of thinking and responses to deal with the humanitarian catastrophe of TB and AIDS co-infection.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, OCTOBER 20
WEDNESDAY, OCTOBER 21
THURSDAY, OCTOBER 22
FRIDAY, OCTOBER 23
SATURDAY, OCTOBER 24
SUNDAY, OCTOBER 25
Conference Program Print | View meeting in 12 hr (am/pm) time
TUESDAY, OCTOBER 20
15:00—19:00
Registration
Naura Springs Hotel Lobby
06:30—08:00
Breakfast at Hotel
Individual Hotels
08:30—11:00
Registration
AICC Karafu Lobby
10:00—11:00
Coffee Available
AICC Lower Lot
11:00—13:00
The TB and AIDS Crisis: Why Are We Not Further Along? (Session with Grand Challenges in Global Health)
AICC Simba Hall
*
Elias Zerhouni,
Sanofi, France
Session Chair
Session Chair
Anne E. Goldfeld,
Children's Hospital Boston, Harvard Medical School, USA
Welcome Remarks
Welcome Remarks
David Baltimore,
California Institute of Technology, USA
Engineering Immunity to Infectious Diseases
Engineering Immunity to Infectious Diseases
Tadataka Yamada,
Mountain Field LLC, USA
The Role of Innovation
The Role of Innovation
13:00—14:30
Joint Lunch with Grand Challenges in Global Health
AICC Lower Lot
14:30—14:45
Keystone Symposia Welcoming Remarks & Orientation
AICC Simba Hall
14:45—17:00
Insights from Natural History of Disease
AICC Simba Hall
Beatrice H. Hahn,
University of Pennsylvania, USA
Natural SIV Infection of Wild-Living Chimpanzees is Associated with Increased Mortality and AIDS-Like Immunopathology
Natural SIV Infection of Wild-Living Chimpanzees is Associated with Increased Mortality and AIDS-Like Immunopathology
Paul D. van Helden,
Stellenbosch University, South Africa
TB Genomics and TB/HIV in Africa
TB Genomics and TB/HIV in Africa
George M. Shaw,
University of Pennsylvania, USA
Genetic Identity, Biological Phenotype and Evolutionary Pathways of Transmitted/Founder Viruses in Acute and Early HIV-1 and SIV Infection
Genetic Identity, Biological Phenotype and Evolutionary Pathways of Transmitted/Founder Viruses in Acute and Early HIV-1 and SIV Infection
17:30—18:00
Poster Setup
Naura Springs Ballroom
17:30—19:00
Social Hour with Lite Bites
Naura Springs Ballroom
18:30—21:00
Poster Session 1
Naura Springs Ballroom
06:30—08:00
Breakfast Included at Hotel
Individual Hotels
08:30—12:00
TB, AIDS and Implications for Novel Interventions
AICC Simba Hall
Stefan H. E. Kaufmann,
Max Planck Institute for Infection Biology, Berlin, Germany
Immune Response to TB and Implications for Overcoming TB and AIDS
Immune Response to TB and Implications for Overcoming TB and AIDS
Anne E. Goldfeld,
Children's Hospital Boston, Harvard Medical School, USA
The Immune Response to TB/HIV Co-Infection: Insights from the Natural History of Disease
The Immune Response to TB/HIV Co-Infection: Insights from the Natural History of Disease
David D. Ho,
Aaron Diamond AIDS Research Center, USA
A Novel Approach to HIV-1 Prevention
A Novel Approach to HIV-1 Prevention
Sébastien Gagneux,
Swiss Tropical and Public Health Institute, Switzerland
Short Talk: Human T-Cell Epitopes of M. Tuberculosis are Evolutionarily Hyperconserved
Short Talk: Human T-Cell Epitopes of M. Tuberculosis are Evolutionarily Hyperconserved
Subash S. Babu,
National Institutes of Health - ICER, India
Short Talk: Negative Regulation of Th17 Responses in Latent Tuberculosis by Regulatory T Cells
Short Talk: Negative Regulation of Th17 Responses in Latent Tuberculosis by Regulatory T Cells
Christian G. Meyer,
Bernhard Nocht Institute for Tropical Medicine, Germany
Short Talk: Human Genetic Factors in Tuberculosis: Candidate Genes and a Genome-Wide Association Study
Short Talk: Human Genetic Factors in Tuberculosis: Candidate Genes and a Genome-Wide Association Study
09:50—10:20
Coffee Break
AICC Upper Lawn
12:00—13:00
Lunch
AICC Upper Lawn
13:00—14:45
TB, AIDS and Implications for Novel Interventions (continued)
AICC Simba Hall
Abdallah S. Daar,
University of Toronto, Canada
Building Capacity for Life Sciences Innovation and Health Product Development in Sub- Saharan Africa
Building Capacity for Life Sciences Innovation and Health Product Development in Sub- Saharan Africa
Robert J. Wilkinson,
University of Cape Town, South Africa
Learning about Immunity to Tuberculosis from HIV Infected People
Learning about Immunity to Tuberculosis from HIV Infected People
Samuel Matoya Nyamweya,
Medical Research Council, Gambia
Short Talk: A Study of Three Biomarkers of Immune Activation and Disease Progression: A Comparison between HIV-1 and HIV-2 Infections
Short Talk: A Study of Three Biomarkers of Immune Activation and Disease Progression: A Comparison between HIV-1 and HIV-2 Infections
14:45—15:15
Coffee Break
AICC Upper Lawn
15:15—17:00
TB, AIDS and Implications for Novel Interventions (continued)
AICC Simba Hall
*
Paul D. van Helden,
Stellenbosch University, South Africa
Elizabeth L. Corbett,
London School of Hygiene and Tropical Medicine/Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi
Impact of Providing Periodic Access to Community-Level Diagnosis of Smear-Positive Disease on Community Control of Infectious Tuberculosis (DETECTB)
Impact of Providing Periodic Access to Community-Level Diagnosis of Smear-Positive Disease on Community Control of Infectious Tuberculosis (DETECTB)
Jeffery S. Cox,
University of California, Berkeley, USA
Short Talk: Dual Regulatory Mechanisms Control ESX-1 Secretion in M. tuberculosis
Short Talk: Dual Regulatory Mechanisms Control ESX-1 Secretion in M. tuberculosis
Anna Helena van't Hoog,
Amsterdam Institute for Global Helath and Devleopment, Netherlands
Short Talk: Factors Associated with Prevalent Pulmonary Tuberculosis in Rural Western Kenya
Short Talk: Factors Associated with Prevalent Pulmonary Tuberculosis in Rural Western Kenya
Bouke C. de Jong,
Institute of Tropical Medicine, Antwerp, Belgium
Short Talk: Genome Sequence of M. africanum, a West African Cause of Human TB More Common in HIV Infected People
Short Talk: Genome Sequence of M. africanum, a West African Cause of Human TB More Common in HIV Infected People
17:30—18:00
Poster Setup
Naura Springs Ballroom
17:30—19:00
Social Hour with Lite Bites
Naura Springs Ballroom
18:30—21:00
Poster Session 2
Naura Springs Ballroom
06:30—08:00
Breakfast Included at Hotel
Individual Hotels
08:30—12:00
Novel Drug Approaches to TB and AIDS
AICC Simba Hall
*
Gail H. Cassell,
Infectious Disease Research Institute, USA
Ronald S. Veazey,
Tulane National Primate Research Center, USA
The Current State of Microbicides
The Current State of Microbicides
Frank Kirchhoff,
University of Ulm, Germany
Semen-Mediated Enhancement of HIV Infection
Semen-Mediated Enhancement of HIV Infection
James C. Sacchettini,
Texas A & M University, USA
Structure-Based Design of New TB Drugs
Structure-Based Design of New TB Drugs
Wafaie W. Fawzi,
Harvard School of Public Health, USA
Short Talk: The Role of Nutrition on Immune Response and Clinical Outcomes in TB and HIV Infection
Short Talk: The Role of Nutrition on Immune Response and Clinical Outcomes in TB and HIV Infection
09:50—10:20
Coffee Break
AICC Upper Lawn
12:00—13:00
Lunch
AICC Upper Lawn
13:00—15:00
Delivery of Care: How Are We Going to Achieve Universal Access?
AICC Simba Hall
*
Anne E. Goldfeld,
Children's Hospital Boston, Harvard Medical School, USA
Mario C. Raviglione,
World Health Organization, Switzerland
Stop TB: The State of Treatment for XDR-, MDR- and Drug-Sensitive TB Thinking out of the Box to Treat TB and Interrupt New Infections on a Global Scale
Stop TB: The State of Treatment for XDR-, MDR- and Drug-Sensitive TB Thinking out of the Box to Treat TB and Interrupt New Infections on a Global Scale
Yohannes Teshale,
Gondar Medical School, Ethiopia
Short Talk: Doctor/Patient Perspective of MDR
Short Talk: Doctor/Patient Perspective of MDR
Yiming Shao,
National Center for AIDS Prevention and Control, China
Evolution of AIDS Control Strategy and Scale Up of AIDS Care Program in China
Evolution of AIDS Control Strategy and Scale Up of AIDS Care Program in China
Gail H. Cassell,
Infectious Disease Research Institute, USA
The MDR and XDR Catastrophe: How Are We Going to Overcome It?
The MDR and XDR Catastrophe: How Are We Going to Overcome It?
15:00—15:30
Coffee Break
AICC Upper Lawn
15:30—17:15
Delivery of Care: Thinking Outside the Box: Developing Need Based Solutions
AICC Simba Hall
*
Christian Lienhardt,
World Health Organisation, Switzerland
Anthony Moll,
Church of Scotland Hospital, South Africa
Responding to MDR/XDR TB and AIDS in a Rural Resource Poor Environment
Responding to MDR/XDR TB and AIDS in a Rural Resource Poor Environment
Sok Thim,
Cambodian Health Committee, Cambodia
Grassroots Solutions to Deliver and Scale up TB and AIDS Care
Grassroots Solutions to Deliver and Scale up TB and AIDS Care
Peter A. Singer,
Grand Challenges Canada, Canada
From Lab to Village
From Lab to Village
17:30—18:00
Poster Setup
Naura Springs Ballroom
17:30—19:00
Social Hour with Lite Bites
Naura Springs Ballroom
18:30—21:00
Poster Session 3
Naura Springs Ballroom
06:30—08:00
Breakfast Included at Hotel
Individual Hotels
08:30—22:30
Developing TB and AIDS Discovery Infrastructure
AICC Simba Hall
Myron E. Essex,
Harvard School of Public Health, USA
Establishing Scientific Infrastructure in an African Field Site: What has the Botswana AIDS Experience Taught us Going Forward
Establishing Scientific Infrastructure in an African Field Site: What has the Botswana AIDS Experience Taught us Going Forward
Odile Ouwe Missi Oukem-Boyer,
Chantal Biya International Reference Centre for Research on HIV/AIDS, Cameroon
Short Talk: The Central Africa Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM) Project: Creation of a Network of Excellence to Improve Clinical Research in Central Africa
Short Talk: The Central Africa Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM) Project: Creation of a Network of Excellence to Improve Clinical Research in Central Africa
Elopy N. Sibanda,
University of Zimbabwe, Zimbabwe
Short Talk: Diagnosing HIV Infection and TB Drug Resistance in Africa, the Starting Point
Short Talk: Diagnosing HIV Infection and TB Drug Resistance in Africa, the Starting Point
Edward A. Nardell,
Brigham and Woman's Hospital, USA
10:30—11:00
Coffee Break
AICC Upper Lawn
11:00—12:35
Overcoming Major Challenges in TB and AIDS Drug and Vaccine Development
AICC Simba Hall
*
Myron E. Essex,
Harvard School of Public Health, USA
Jerald C. Sadoff,
Crucell Vaccine Institute, Janssen Pharmaceutical Companies of Johnson & Johnson, Netherlands
Aeras TB Vaccine Development
Aeras TB Vaccine Development
Helen McShane,
Jenner Institute, UK
Short Talk: Results from Clinical Trials with a New TB Vaccine, MVA85A, in HIV-Infected People
Short Talk: Results from Clinical Trials with a New TB Vaccine, MVA85A, in HIV-Infected People
David M. Lewinsohn,
Oregon Health & Science University, USA
Short Talk: MR1-Dependent Presentation of Mycobacterium tuberculosis Antigens to Human CD8+ T Cells
Short Talk: MR1-Dependent Presentation of Mycobacterium tuberculosis Antigens to Human CD8+ T Cells
12:45—13:45
Lunch
AICC Upper Lawn
13:45—17:00
Overcoming Major Challenges in TB and AIDS Drug and Vaccine Development
AICC Simba Hall
Mark B. Feinberg,
IAVI International AIDS Vaccine Initiative, USA
Declined: The Disappointing Results of the STEP Trial: How do They Advance our Understanding of the Challenges of HIV Vaccine Development and Inform the Next Steps Moving Forward?
Declined: The Disappointing Results of the STEP Trial: How do They Advance our Understanding of the Challenges of HIV Vaccine Development and Inform the Next Steps Moving Forward?
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC, France
Declined: Investigation of the Immune Response to AIDS and Novel Vaccine Design
Declined: Investigation of the Immune Response to AIDS and Novel Vaccine Design
Phyllis J. Kanki,
Harvard School of Public Health, USA
HIV Diversity in Africa: What We have Learned for Vaccine and Drug Development and Delivery
HIV Diversity in Africa: What We have Learned for Vaccine and Drug Development and Delivery
Jayne S. Sutherland,
Medical Research Council, Gambia
Short Talk:
Short Talk:
Tanjore S. Balganesh,
Institute of Genomics and Integrative Biology - CSIR-IGIB, India
Discovery of Anti-Tuberculosis Agents: Building on a Decade of Learning!
Discovery of Anti-Tuberculosis Agents: Building on a Decade of Learning!
*
Alan Sher,
NIAID, National Institutes of Health, USA
Immunologic Determinants of Mycobacterial Associated Immune Reconstitution Inflammatory Syndrome (IRIS) in a Murine Experimental Model
Immunologic Determinants of Mycobacterial Associated Immune Reconstitution Inflammatory Syndrome (IRIS) in a Murine Experimental Model
*
Stefan H. E. Kaufmann,
Max Planck Institute for Infection Biology, Berlin, Germany
Closing Remarks
Closing Remarks
14:50—15:20
Coffee Break
AICC Upper Lawn
17:30—19:00
Social Hour with Lite Bites
Naura Springs Ballroom
18:00—21:00
Entertainment
Naura Springs Ballroom
06:30—08:30
Breakfast Included at Hotel
Individual Hotels
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
